Skip to main content

Advertisement

SpringerLink
Log in

Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

The functional assessment of cancer therapy epidermal growth factor receptor inhibitor 18 (FACT-EGFRI-18) is a patient-reported outcomes questionnaire developed to assess the effect of EGFRI on health-related quality of life (HRQoL).

Methods

Ten native-speaking residents of The Netherlands who reported EGFRI-associated mucocutaneous adverse events (mcAEs) were administered the questionnaire. Patients were subsequently asked a standardized series of questions about the items’ personal relevance.

Results

Responses reflected a major negative impact of mcAEs due to EGFRI on physical, social/emotional, and functional domains. In some cases, especially in the social/emotional domain, the responses to the qualitative interview indicated a greater impact on HRQoL than the numerical ratings previously selected for the Dutch FACT-EGFRI-18 questions.

Conclusions

Based on these interviews, we identified that the physical items associated with mcAEs interfere most with HRQoL. The results suggest that the FACT-EGFRI-18 can be applied to measure mcAE-related HRQoL in cancer patients undergoing EGFRI therapy. In addition, patients feel the need to rate their symptom burden, too, and we recommend additional adverse event items to be incorporated into the questionnaire.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Balagula Y, Garbe C, Myskowski PL, Hauschild A, Rapoport BL, Boers-Doets CB, Lacouture ME (2011) Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol 50(2):129–146

    Article  PubMed  CAS  Google Scholar 

  2. Iacovelli L (2007) Clinical management of EGFRI-associated dermatologic toxicities: pharmacy perspective. Oncology (Williston Park) 21(11 Suppl 5):31–33

    Google Scholar 

  3. Lacouture ME, Melosky BL (2007) Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Lett 12(6):1–5

    PubMed  CAS  Google Scholar 

  4. Perez-Soler R, van Cutsem E (2007) Clinical research of EGFR inhibitors and related dermatologic toxicities. Oncology (Williston Park) 21(11 Suppl 5):10–16

    Google Scholar 

  5. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW (2007) Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 56(2):317–326

    Article  PubMed  Google Scholar 

  6. Wagner LI, Lacouture ME (2007) Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park) 21(11 Suppl 5):34–36

    Google Scholar 

  7. Cleeland CS (2007) Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr 37:16–21

    Article  PubMed  Google Scholar 

  8. Fayers PM, Hand DJ, Bjordal K, Groenvold M (1997) Causal indicators in quality of life research. Qual Life Res 6(5):393–406

    Article  PubMed  CAS  Google Scholar 

  9. Wilson IB, Cleary PD (1995) Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 273(1):59–65

    Article  PubMed  CAS  Google Scholar 

  10. Ferrans CE, Zerwic JJ, Wilbur JE, Larson JL (2005) Conceptual model of health-related quality of life. J Nurs Scholarsh 37(4):336–342

    Article  PubMed  Google Scholar 

  11. Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, Rosenbaum SE, Lacouture ME (2010) Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 116(16):3916–3923

    Article  PubMed  Google Scholar 

  12. Cella DF (1994) Quality of life: concepts and definition. J Pain Symptom Manag 9(3):186–192

    Article  CAS  Google Scholar 

  13. Ratanatharathorn V, Sirilerttrakul S, Jirajarus M, Silpakit C, Maneechavakajorn J, Sailamai P, Sirisinha T (2001) Quality of life, functional assessment of cancer therapy-general. J Med Assoc Thail 84(10):1430–1442

    CAS  Google Scholar 

  14. Wagner LI, Lai SE, Aneja M, LoRusso P, Perez-Soler R, O'Brien B et al (2007) Development of a functional assessment of side-effects to therapy (FAST) questionnaire to assess dermatology-related quality of life in patients treated with EGFR inhibitors (EGFRI): the FAST-EGFRI. J Clin Oncol ASCO Meet Abstr 25(18 Suppl):19532

    Google Scholar 

  15. U.S. Food and Drug Administration (2009) Guidance for industry: patient-reported outcomes measure: use in medical product development to support labeling claims. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf

  16. Willke RJ, Burke LB, Erickson P (2004) Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials 25(6):535–552

    Article  PubMed  Google Scholar 

  17. Calvert MJ, Freemantle N (2003) Use of health-related quality of life in prescribing research. Part 1: why evaluate health-related quality of life? J Clin Pharm Ther 28(6):513–521

    Article  PubMed  CAS  Google Scholar 

  18. Calvert MJ, Freemantle N (2004) Use of health-related quality of life in prescribing research. Part 2: methodological considerations for the assessment of health-related quality of life in clinical trials. J Clin Pharm Ther 29(1):85–94

    Article  PubMed  CAS  Google Scholar 

  19. National Cancer Institute Cancer Therapy Evaluation Program (2010) Common terminology criteria for adverse events and common toxicity criteria [v4.0]. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_v40

  20. Wagner LI, Rosenbaum SE, Gandhi M, Webster K, Aneja MS, Cella D et al (2010) Development of a functional assessment of chronic illness therapy questionnaire to assess dermatology-related quality of life in patients treated with EGFR inhibitors: FACT-EGFRI. J Clin Oncol 28 [15s], (suppl; abstr 9046)

  21. FACIT.org (2010) Functional Assessment of Chronic Illness Therapy (FACIT). http://www.facit.org/FACITOrg/Questionnaires

  22. Webster K, Cella D, Yost K (2003) The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 1:79–84

    Article  PubMed  Google Scholar 

  23. Bonomi AE, Cella DF, Hahn EA, Bjordal K, Sperner-Unterweger B, Gangeri L, Bergman B, Willems-Groot J, Hanquet P, Zittoun R (1996) Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res 5(3):309–320

    Article  PubMed  CAS  Google Scholar 

  24. Eremenco SL, Cella D, Arnold BJ (2005) A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Eval Health Prof 28(2):212–232

    Article  PubMed  Google Scholar 

  25. Cella D, Webster K (1997) Linking outcomes management to quality-of-life measurement. Oncology (Williston Park) 11(11A):232–235

    CAS  Google Scholar 

Download references

Acknowledgments

The authors thank the participants for their collaboration in this study and their valuable contributions.

Conflict of interest

The authors declare no conflicts of interest. All authors had full control of all primary data and agree to allow the journal to review the data, if requested.

Author information

Authors and Affiliations

  1. Department of Clinical Oncology, Leiden University Medical Centre, PO Box 9600, 2300 RC, Leiden, The Netherlands

    Christine B. Boers-Doets, Hans Gelderblom & Johan W. R. Nortier

  2. Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Mario E. Lacouture

  3. Division of Otolaryngology and Head and Neck Surgery, Department of Surgery, City of Hope, Duarte, CA and Medical-Dental Staff, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Joel B. Epstein

  4. Department of Medical Psychology, Leiden University Medical Centre, Leiden, The Netherlands

    Ad A. Kaptein

Authors
  1. Christine B. Boers-Doets
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans Gelderblom
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mario E. Lacouture
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joel B. Epstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Johan W. R. Nortier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ad A. Kaptein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christine B. Boers-Doets.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boers-Doets, C.B., Gelderblom, H., Lacouture, M.E. et al. Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events. Support Care Cancer 21, 1919–1926 (2013). https://doi.org/10.1007/s00520-013-1752-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-013-1752-4

Keywords

Search

Navigation